News publication
Everything we hold that gpnvaccines.com published.
Every article we hold from gpnvaccines.com.
GPN Vaccines, an Adelaide biotech, has closed a A$18 million Series B1 that beat its 15 million target, co-led by Forepont Capital and Mike Gregg, with Kern Capital joining as a new investor.
Deals recorded from gpnvaccines.com's coverage. A round is listed once, however many of their articles mention it.
| Company | Stage | Announced | Amount | Investors |
|---|---|---|---|---|
| GPN Vaccines | Series B | 7 Jun 2024 | $18m |
Companies named in gpnvaccines.com's articles, most-covered first.
| Company | What it does | Articles |
|---|---|---|
| GPN Vaccines | 1 | |
| Health Communication Network | 1 | |
| Shearwater Capital | 1 | |
| WiseTech | 1 |
Investors named in gpnvaccines.com's articles, most-covered first.
| Investor | What it does | Articles |
|---|---|---|
| Forepont Capital | 1 | |
| Kern Capital | 1 |